You have 9 free searches left this month | for more free features.

Condition

Head and Neck Squamous Cell Carcinoma (HNSCC) (1)

Lymphoma (1)

Solid Tumors (1)

Overall Status

Active, not recruiting (1)

Completed (1)

Sign in for free

Phase

phase 1 (1)

phase 2 (1)

Sponsor

Merck Sharp & Dohme Corp. (1)

Merck Sharp & Dohme LLC (1)

Collaborator

Intervention

pembrolizumab (2)

ulevostinag (2)

Study Documents

Intervention Type

biological (2)

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

ulevostinag

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Solid Tumors, Lymphoma Trial in Worldwide (Ulevostinag, Pembrolizumab)

Completed

Solid Tumors
Lymphoma

Ulevostinag
Pembrolizumab

Birmingham, Alabama
+18 more

Jun 10, 2022

Head and Neck Squamous Cell Carcinoma (HNSCC) Trial in Worldwide (Ulevostinag, Pembrolizumab)

Active, not recruiting

Head and Neck Squamous Cell Carcinoma (HNSCC)

Ulevostinag
Pembrolizumab

Los Angeles, California
+33 more

Oct 4, 2021